Source - LSE Regulatory
RNS Number : 5334U
Abingdon Health PLC
06 April 2021
 

 

Director Dealing

 

York, U.K. 6th April 2021:  Abingdon Health (AIM:ABDX) ("Abingdon" or "the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, announces that Melanie Ross, Chief Financial Officer, has today purchased 5,338 ordinary shares of 0.025p each in the Company ("Ordinary Shares") at a price of 93.45 pence per Ordinary Share. Prior to this, Melanie did not hold an interest in any Ordinary Shares, and therefore has a resultant interest in 0.01% of the Company's issued share capital.

 

- Ends-

 

Enquiries:

Abingdon Health plc



Chris Yates

Chief Executive Officer

Via Consilium

Melanie Ross

Chief Financial Officer


Chris Hand

Non-Executive Chairman





N+1 Singer

Sole Broker and Nominated Adviser

Shaun Dobson, Peter Steel,


Tel: +44 (0) 20 7496 3000

Alex Bond (Corporate Finance)


Tom Salvesen (Corporate Broking)





Consilium

Financial PR

Tel: +44 (0) 203 709 5700

Matthew Neal

abingdonhealth@consilium-comms.com

Mary-Jane Elliott 



Lindsey Neville








 

About Abingdon Health

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

https://www.abingdonhealth.com/



 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Melanie Ross

 

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Abingdon Health plc

b)

 

LEI

 

213800XFI4WV3FBILO20

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.025 pence each

 



Identification code

GB00BLF79J41



b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




93.45 pence

5,338







d)

 

Aggregated information

N/A single transaction



- Aggregated volume




- Price




e)

 

Date of the transaction

 

 

6 April 2021

f)

 

Place of the transaction

 

London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBDGDSBXGDGBL
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.